Dr Kelvin Chan is a Medical Oncologist at the Sunnybrook Odette Cancer Centre, a Professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He specializes in GI oncology and Head and Neck oncology. He has recently completed his PhD in Biostatistics (focusing on statistical methods in health economic evaluations) at the Dalla Lana School of Public Health, University of Toronto.
As a clinical epidemiologist and biostatistician, Dr. Chan’s research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics. He is the Co-Director at the Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society (CCS).
Professionally, Dr Chan has an interest in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including membership at the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), the Committee to Evaluate Drug (CED) and the Interim Chair for the Ontario Steering Committee of Cancer Drugs (OSCCD), Ontario MOHLTC and Cancer Care Ontario. He is also the Clinical Lead for the Provincial Drug Reimbursement Programs (PDRP) at Ontario Health.
Dr. Wanrudee Isaranuwatchai is a Research Scientist and the Director of the Centre for Excellence in Economic Analysis Research, St. Michael’s Hospital. She is also an Assistant Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto. Her research focuses on applying health economics methods in the real world setting and advancing methods in economic evaluations. She has experience conducting economic evaluations using person-level data and decision modeling. She has collaborated with researchers and decision-makers in various areas to help communicate the value of health initiatives using economic evidence. Dr. Isaranuwatchai is dedicated to promoting the use of evidence in healthcare decision making.
Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship and is a Professor in the Faculty of Health Sciences, Simon Fraser University. He is currently Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a pan-Canadian research centre providing interdisciplinary leadership in health economics, services, policy and ethics research. Stuart is also a Distinguished Scientist in Cancer Control Research at the BC Cancer Agency, a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK. Over the past 20 years, Stuart’s main research interests have focused on research into developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.
Dr. Mina Tadrous is currently a scientist at Women’s College Hospital (WCH) Institute for Health System Solutions and Virtual Care (WIHV). He is also an investigator with the Ontario Drug Policy Research Network (ODPRN) and ICES adjunct scientist. Mina’s research interests lie in drug policy research and the post-marketing surveillance of safety and effectiveness of medications. He completed a PhD in pharmacoepidemiology at the University of Toronto and previously completed a Masters in Health Outcomes and Policy Research at the University of Tennessee, and a Doctor of Pharmacy at Albany College of Pharmacy. He also completed a pharmacy residency in Drug Information and health Outcomes at the University of Tennessee and St. Jude Children’s Research Hospital. He is a practicing pharmacist who has worked in a variety of clinical settings.
Principal Knowledge User
Suzanne McGurn is President & CEO of CADTH.
Prior to joining CADTH, Ms. McGurn was the Assistant Deputy Minister of Institutional Services at the Ontario Ministry of the Solicitor General. Ms. McGurn also served for five years as Ontario’s Assistant Deputy Minister of the Drugs and Devices Division and the Executive Officer of Ontario’s Public Drug Programs. She also led the implementation of the pan-Canadian Pharmaceutical Alliance and served as its first Chair.
In addition to her understanding of the complex issues surrounding the management of pharmaceuticals, medical devices, procedures, and health systems in Canada, Ms. McGurn brings significant experience in governance and patient engagement in the health system. Her past roles on the CADTH Board of Directors include Vice-Chair and Ontario Representative. Further, she has served as the Executive Director of the Alzheimer Society of Kingston, Frontenac, Lennox & Addington and as a Senior Manager at the Kingston, Frontenac, Lennox & Addington Community Care Access Centre.
Ms. McGurn holds both a Bachelor of Nursing Sciences and a Master of Public Administration from Queen’s University.
Michael Sherar, PhD, was previously the President and CEO of Cancer Care Ontario.
Riaz Alvi is the Director of Epidemiology and Performance Measurement at the Saskatchewan Cancer Agency. He is also an Adjunct Faculty Member with the University of Saskatchewan’s College of Graduate Studies. Riaz has worked at the Saskatchewan Cancer Agency for 19 years and as Director for the last 13 years. His interests include; cancer surveillance, performance and outcomes measurement, patient reported outcomes, health equity, Real World Evidence, and cancer in indigenous populations.
Dr. Melissa Brouwers joined the University of Ottawa as the Director of the School of Epidemiology and Public Health in September, 2018. Prior to her appointment here, Dr. Brouwers was at McMaster University in Hamilton, where she was a Professor in the Departments of Oncology (primary) and Health Research Methodology, Evidence and Impact (affiliate). In addition, she served as the Director of the Program in Evidence-based Care, the guidelines program for Cancer Care Ontario; the Director of the Centre for Evidence-based Implementation at Hamilton Health Sciences; and the Deputy Director of the Escarpment Cancer Research Institute.
Claire de Oliveira
Claire de Oliveira is a health economist at the Centre for Addiction and Mental Health, an associate professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, and an adjunct scientist at ICES. In addition, she is the Expert Lead in cancer economics at the Canadian Partnership Against Cancer, an associate member and co-program lead for Health Technology Assessment at the Canadian Centre for Applied Research in Cancer Control, and collaborator at the Toronto Health Economics Technology Assessment Collaborative.
Her main areas of research are in health economics and health services research applied to mental health, cancer and child health. Her main areas of cancer-related research include the use of administrative health care data to measure health services utilisation and costs, and the assessment of value for money in cancer care.
Dr. Robin McLeod received a B.Sc. and MD from the University of Alberta. Following this, she completed training in General Surgery at the University of Toronto, Colorectal Surgery at the Cleveland Clinic, as well as training in clinical epidemiology at McMaster University before joining the faculty at the University of Toronto. She is a Fellow of the Royal College of Physicians and Surgeons of Canada, a Fellow of the American College of Surgeons and a fellow ad hominem of the Royal College of Surgeons of Edinburgh. She is a Diplomate of the American Board of Surgery and the American Board of Colorectal Surgery.
Dr. McLeod is a Professor in the Department of Surgery and the Institute of Health Policy Management and Evaluation and Vice Chair, Quality and Performance, in the Department of Surgery at the University of Toronto. In the latter position, she has led the Best Practice in Surgery initiative which supports quality initiatives in the University of Toronto affiliated hospitals. Dr. McLeod is also currently the Vice President of Clinical Programs and Quality Initiatives at Cancer Care Ontario, the provincial agency which oversees all cancer services in Ontario.
Dr. McLeod is a past president of the Canadian Association of General Surgeons and the Society for Surgery of the Alimentary Tract and a past Regent of the American College of Surgeons and President Elect of the American Surgical Association. She is also an honorary member of the Royal College of Edinburgh, the Association of Coloproctology of Great Britain and Ireland and a Life Member of the Colorectal Surgical Society of Australia and New Zealand. She was the founding Chair of Evidence Based Reviews in Surgery, an internet journal club jointly sponsored by the Canadian Association of General Surgeons & American College of Surgeons.
Dr McLeod’s clinical and research interests are colorectal cancer, inflammatory bowel disease, evidence based medicine, quality and knowledge translation. She has led several multicentre clinical trials and quality initiatives and has authored over 350 peer reviewed articles and 50 book chapters.
I am a biostatistician, and did my undergraduate and master’s level training in mathematics at the University of Cambridge in England. After graduating, I worked for two years at the Centre for Applied Medical Statistics in the Department of Public Health and Primary Care at the University of Cambridge. This was my first experience working with real researchers on real data, and I enjoyed it so much I decided I wanted to be a researcher myself. I did my PhD in biostatistics at the University of Toronto, then a post-doctoral fellowship at the University of Waterloo, before moving to McMaster University. There, I set up a research program on statistical methods for longitudinal data and economic evaluations, and I also taught and collaborated on clinical projects. I now work at SickKids in the Child Health Evaluative Sciences program.
Avram (Avi) Denburg
Dr. Avi Denburg’s research centres on the analysis and strengthening of childhood cancer care systems, with specific focus on issues related to pharmaceutical policy and drug access. He has ongoing collaborations in the field of global oncology with a range of national and international partners, including the Union for International Cancer Control, the World Health Organization, and the Pan-American Health Organization. Dr. Denburg is Immediate Past Chair of the Essential Medicines Committee for the International Society of Pediatric Oncology and co-founder of Access to Childhood Cancer Essentials, a global initiative to improve access to essential medicines and therapeutics for children with cancer. He serves as an expert member of the pan-Canadian Oncology Drug Review for the Canadian Agency for Drugs and Technologies in Health and the Ontario Steering Committee on Cancer Drugs.
Jaclyn is a health economist and manager of the Pharmacoeconomics Research Unit at Cancer Care Ontario, where she helps assess and interpret cost-effectiveness of new therapies. Her interests include economic evaluations, health services research, and real-world evidence in oncology, and in enhancing the role of pharmacoeconomic evidence in reimbursement decision-making. She is pursuing her PhD in Health Services Research at the University of Toronto.
Winson Y. Cheung, MD, MPH, FRCPC is a medical oncologist and a nationally and internationally recognized health services researcher and real-world data scientist. He is currently appointed as Full Professor in the Departments of Oncology, Medicine, and Community Health Sciences at the University of Calgary where he is also the Provincial Director of Health Services Research. Prior to his leadership recruitment to Calgary in 2017, he worked at BC Cancer in Vancouver for 7 years.
Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Masters of Public Health degree at Harvard University. He specializes in the management of gastrointestinal malignancies. He is the recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Canadian Cancer Trials Group Dr Ralph Meyer Award, the Novartis Oncology Canadian Investigator Mentor Award, and the Multinational Association of Supportive Care in Cancer Investigator Award. He has secured over 15 million dollars in competitive grant funding, including from CIHR and Canadian Cancer Society. He has also been invited to be a reviewer on national and international grant panels as well as a member on scientific program committees for the American Society of Clinical Oncology and the Canadian Cancer Research Alliance.
Dr. Cheung’s primary research interest is using big data for health services and outcomes research as well as generating real-world evidence across all tumor sites. His projects focus on understanding the interplay of various patient, physician, and system level factors that drive practice patterns in the population-based setting and learning how costs and processes can be modified to better inform care. The overarching goal of his work is to ensure that cancer care is appropriately accessed and delivered to patients in an equitable and effective manner. His own research and those of his trainees appear frequently in high impact scientific journals. To date, he has published more than 175 peer-reviewed manuscripts. He enjoys mentoring trainees, many of whom have proceeded to develop successful academic careers. Over two dozen of his trainees have received ASCO Merit Awards and additional grants since 2010.
Dr. Craig Earle is a medical oncologist at Sunnybrook’s Odette Cancer Centre in Toronto, Vice-President of Cancer Control at the Canadian Partnership Against Cancer, a Senior Scientist at the Institute for Clinical Evaluative Sciences, and a Professor of Medicine at the University of Toronto. He is past Chair of the Ontario Steering Committee for Cancer Drug Programs and is a current member of the pan-Canadian Oncology Drug Review Expert Review Committee. Dr. Earle originally trained and practiced in Ottawa, after which he spent 10 years between 1998 – 2008 in Boston at Harvard Medical School and the Harvard School of Public Health. Between 2008-2017 he was Director of Health Services Research and Head of Clinical Translation at the Ontario Institute for Cancer Research.
Dr. Nicole Mittmann is the Chief Scientist and Vice President of Evidence Standards at the Canadian Agency for Drugs and Technologies in Health (CADTH). At CADTH, Nicole is leading a team conducting health economics, scientific reviews and information services. Other initiatives include patient engagement and real-world evidence. Formerly, the Chief Research Officer at Cancer Care Ontario (CCO), the provincial cancer agency in Ontario she constructed and implemented the first strategy and framework for research at the organization.
In her academic capacity, Dr. Mittmann holds a faculty position as an Assistant Professor at the University of Toronto in the Department of Pharmacology and Toxicology and is an Associate Scientist at Sunnybrook Health Sciences Centre. She has conducted and collaborated on notable research in the areas of economic evaluations, outcomes research and drug/patient safety. Research methodologies include the examination of large databases, economic methodologies and decision analysis. She remains an active researcher, with more than 170 peer-reviewed journal articles.
Most recently, she has been funded by Genome Quebec to examine the cost-effectiveness of breast cancer genetic tests and the Ontario Institute for Cancer Research/Cancer Care Ontario to determine the burden of cancer from a Canadian health system perspective and the development of costing algorithms for chemotherapy and radiation therapy.
Dr. Mittmann is also the co-chair of the Committee on Economic Analysis (CEA) at the Canadian Cancer Trials Group (CCTG). Responsibilities include embedding economic parameters in clinical trials, economic evaluations and guideline development. She was the lead author and investigator on the establishment of economic guidelines for oncology products in partnership with CCTG and the Canadian Agency for Drugs and Technologies in Health (CADTH).
Gunita Mitera, PhD – Gunita is the Executive Director of the Canadian Association of Provincial Cancer Agencies (CAPCA).
Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation. Her research focuses on evaluating the adoption of new genomic technologies in clinical practice. She also conducts public and patient engagement research to advance health technology assessment and health service delivery. Dr. Bombard is active in numerous international policy advisory committees; her research informs policy development in this area. In 2014, Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research in 2011. Recently, she has been awarded a CIHR Foundation grant as an Early Career Investigator, and she holds a CIHR New Investigator Award.
Dr. Bombard holds a Fellowship from Yale University (Health Policy), a Fellowship from the Memorial Sloan-Kettering Cancer Center (Cancer Genomics) and a Fellowship from the University of Toronto (Health Services Research).
Prior to becoming Director of the Canadian Cancer Trials Group on September 1, 2014, Dr. Dancey was Director, Translational Research – Clinical at Canadian Cancer Trials Group. She is also Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN) and from 2008-2015 she was Director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research. Prior to joining the Canadian Cancer Trials Group, Dr. Dancey was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch. Dr. Dancey received her MD from the University of Ottawa and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the Canadian Cancer Trials Group and continued her fellowship training at the Institut Gustave Roussy in France. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology. She is also Professor in the Department of Oncology at Queen’s University.
Jeffrey Hoch received his PhD in health economics from the Johns Hopkins School of Public Health. He also holds a Masters in Economics from Johns Hopkins University, and a Bachelor of Arts degree in Quantitative Economics and Decision Sciences from the University of California at San Diego. Currently, he is a Professor and Chief of the Division of Health Policy and Management in the Department of Public Health Sciences and the Associate Director of the Center for Healthcare Policy and Research at the University of California at Davis.
Professor Hoch teaches courses in health economics and researches value in health care. He has contributed more than 160 peer-reviewed articles to the scientific literature. As an award-winning teacher, Professor Hoch has taught Health Economics and Economic Evaluation classes throughout the world, giving over 200 invited presentations in 15 countries.
Dr. Pechlivanoglou is a scientist at the Hospital for Sick Children’s Research Institute and an assistant professor at the University of Toronto’s Institute of Health Policy Management and Evaluation. His research interests focus on methods and applications of decision analysis in health economics, bridging evidence synthesis, administrative data and decision analysis, and the application and extension of predictive models in health economics. He has received funding from the Canadian Institute for Health Research, the Canadian Respiratory Research Network and more recently the Ontario Early Researcher Award around the economics of pre-term birth prevention, the economic evaluation of oncology interventions in children and adolescents, the use of decision analysis in pediatric clinical trial design and the economic impact of COPD in adults.
Dr. Maureen Trudeau is a Medical Oncologist, specializing in breast cancer. She is an Affiliate Scientist at the Sunnybrook Research Institute and Professor of Medicine at the University of Toronto. As former co-chair and now member of the Breast Cancer Disease Site Group in the Program in Evidence-Based Care of Cancer Care Ontario, Dr. Trudeau is involved in practice guideline development. She has also been involved with the approval for funding of cancer drugs provincially since 2006; and nationally since 2012; as Vice Chair and now Chair for the Expert Review Committee of the Pan Canadian Oncology Drug Review.
Brent Fraser is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH drug products and services including the CADTH Common Drug Review (CDR), the pan-Canadian Oncology Drug Review (pCODR).
Brent is dedicated to building a team-based, client-oriented culture that values leadership, excellence, collaboration, and responsiveness. He champions customer service, business discipline, and ongoing process improvement, and he challenges his team to deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known for his strength as a thoughtful, listening, and collaborative leader who is adept at translating evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with almost two decades of strategic experience within the largest public drug plan in the country.
Prior to joining CADTH in 2015, Brent held a variety of positions within the Ontario Public Drug Programs, where he was a key leader in the development of a pan-Canadian approach to pharmaceutical negotiations. Prior to that he was a pharmacist at the Hospital for Sick Children in Toronto.
Sang Mi Lee
Heather Logan joined CADTH in January 2019 as the Senior Advisor, Pharmaceutical Reviews. For a period of approximately one year soon after joining CADTH, Heather took on responsibility for the CADTH Pharmaceutical Review Directorate as the Acting Vice President. Now back in the Senior Advisor role, Heather is responsible for specific projects and initiatives such as transition of the Cancer Drug Implementation Advisory Committee (CDIAC) to CADTH, as the Executive Sponsor of CADTH’s CAR T-cell review process, and as a primary point of contact with federal and provincial decision makers and stakeholders.
With over 20 years’ experience working with local and national decision-makers, Heather is known for her facilitative leadership style, and her ability to catalyze change. With a background as a Nursing Officer in the Canadian Armed Forces, media spokesperson, health care administrator, policy leader, and systems leader, Heather’s diverse background is instrumental in helping her seeing multiple sides to every issue.
Married with two children, Heather has an MHSc and a BScN from the University of Toronto
Mary Argent-Katwala is a healthcare professional focused on oncology with over fifteen years of experience in senior roles in the commercial, non-profit and consulting sectors. Mary’s most recent position was Director, Diagnosis & Clinical Care at the Canadian Partnership Against Cancer where she led the development and implementation of evidence-based tools, standards and guidelines that addressed key issues in the diagnosis and treatment of cancer. Prior to joining the Partnership, Mary worked for the Canadian Cancer Society as Director of Research where she acted as scientific advisor and implemented key aspects of the Society’s nationwide strategic plan. Before moving to Canada, Mary worked at the Decision Resources Group as a consultant in biotechnology, life sciences and med tech in the G7. Mary holds a PhD from the Institute of Cancer Research, University of London, UK, and an MA from Cambridge University, UK. Mary enjoys using twitter and LinkedIn but she is a Facebook refusenik.
Carole Chambers is the Pharmacy Director of Cancer Services with the Alberta Health Services, with over 50 peer reviewed publications. She currently serves on the provincial advisory group for pCODR and the panCanadian pricing negotiating teams dealing with access issues to new oncology agents. She also joined the Board of the Institute for Safe Medication Practice (ISMP-Canada) .Carole has remained active in ISOPP since completing her term as ISOPP President in 2010 as she sits on the JOPP Editorial Board, served as Research Committee Chair 2016-18, and is a member of the team generating the ISOPP virtual journal club. She holds an ISOPP Fellowship as well as the Helen McKinnon award recognizing her significant contribution to ISOPP and oncology pharmacy practice.
Scott Gavura is Director, Provincial Drug Reimbursement Programs at Cancer Care Ontario, and has held this role since 2007. In this position Scott is responsible for the strategic management of CCO’s cancer drug reimbursement programs as well as two non-drug patient access programs. Scott has been working for over 20 years to improve the use of medicines in roles ranging from front-line service as a community and hospital pharmacist to multiple roles in government and professional associations. Scott has a Bachelor of Science in Pharmacy degree and an MBA from the University of Toronto.
Danica Lister Wasney
Danica Wasney is a pharmacist at CancerCare Manitoba, working in both the Department of Pharmacy and the Provincial Oncology Drug Program. In this role, she participates in the provincial review and implementation of new systemic therapies for oncology-hematology. She is a past member of the Expert Review Committee for the pan-Canadian Oncology Drug Review (pCODR) at the Canadian Agency for Drugs and Technologies in Health (CADTH).
She has practiced as a clinical pharmacist on multidisciplinary teams providing care for patients with breast, colorectal, thoracic, gynecologic, neuro-oncology, and hematologic malignancies.
She graduated from the Faculty of Pharmacy at University of Manitoba and completed an Accredited Hospital Pharmacy Residency at The Ottawa Hospital. She is a Board Certified Oncology Pharmacist (BCOP) with the Board of Pharmaceutical Specialties. She participates in several initiatives with the Canadian Association of Pharmacy in Oncology (CAPhO); she is a member of the Research Committee and an author/presenter for multiple projects of the Education Committee.
Sylvie Bouchard holds a bachelor’s degree in Pharmacy from Université Laval in Québec city (1988). She
also has a diploma (1989) and a master’s degree (1992) in Hospital Pharmacy from Université Laval
(Faculty of Pharmacy), and an MBA in Corporate Management (2001), also from Université Laval (Faculty
of Business Administration).
Sylvie Bouchard was a hospital pharmacist and hospital pharmacy manager, first at the Centre hospitalier
affilié universitaire de Québec (CHA), from 1988 to 2004, then at the Hôtel-Dieu de Québec, part of the
Centre hospitalier universitaire de Québec (CHUQ), from 2006 to 2010. She has worked in several clinical
departments and shown a strong interest in intensive care. In 2001, Ms. Bouchard introduced to the CHA
the first robot for distribution of medications in Québec.
She joined the Conseil du médicament in April 2010, which became the Institut national d’excellence en
santé et en services sociaux (INESSS) in 2011, where she has held various management positions over the
years. Since April 2016, she has headed the Direction du médicament, a role involving the evaluation of
medications for inclusion on the lists, the optimal use of drug products and medical protocols with
collective prescriptions associated.
Michèle de Guise
Michèle de Guise has been the Director of health services and technology evaluation for the Institut national d’excellence en santé et en services sociaux (INESSS) in Québec since July 2015. She graduated from the Université de Montréal as a cardiologist and also completed a Master’s degree in Management at McGill University. Before joining INESSS, she held various positions at the Centre hospitalier de l’Université de Montréal, including Assistant Chief Medical Officer for Quality and Practice Improvement.
Marc Geirnaert graduated from the University of Manitoba with his Bachelor of Sciences in Pharmacy in 2002. Since January 2003, Marc has worked at CancerCare Manitoba in various clinics: Lymphoproliferative disorders, Bone Marrow Transplant, Genitourinary and Central Nervous System. In 2011, Marc became a Senior Pharmacist in the Department of Pharmacy and since 2014, is the Director of the Provincial Oncology Drug Program. Marc sits on various committees regarding new drugs for oncology and hematology such as the Provincial Advisory Group committee at pCODR and the Cancer Drug Implementation Advisory Committee.
Scott Livingstone is the first Chief Executive Officer (CEO) of the Saskatchewan Health Authority (SHA). The SHA is the single biggest public sector employer in Saskatchewan history and one of the largest health organizations in Canada.
Prior to joining the SHA, Scott was the President and CEO of the Saskatchewan Cancer Agency. He has also served as the CEO of the Saskatchewan Health Information Network (now eHealth Saskatchewan).
Scott has chaired and participated on a number of provincial and national boards representing Saskatchewan and the health sector in the areas of eHealth, shared services, evidence-based drug assessment and sustainability of cancer care.
A pharmacist by training, Livingstone has dedicated his career to providing executive leadership that builds strong organizational culture focused on patients and families and continuous quality improvement.
Marjorie Morrison is the Executive Director of the Canadian Association for Population Therapeutics / Association Canadienne pour la Thérapeutiques des Populations (CAPT-ACTP). Previously, Marjorie served as the Chief Executive Officer of the Canadian Cancer Action Network for 10-years where she worked with pan-Canadian patient advocacy organizations, cancer control stakeholders and health leaders to implement multi-sectoral initiatives that embedded the lived experiences and perspectives of patients and caregivers in Canada’s cancer strategy. Prior to relocating to Toronto in 2008, she was the Executive Director of a community-based support and resource centre for those living with breast cancer in Eastern Ontario.
Marjorie is an alumna of the University of Regina and is currently a Master of Health Administration candidate with the Johnson Shoyama School of Public Policy, Regina, Saskatchewan.
Rebecca Mercer is the Network Manager for the Canadian Centre for Applied Research in Cancer Control (ARCC). She has significant experience with knowledge translation and mobilization, and an interest in facilitating information transfer among stakeholders. Rebecca received her PhD in Medical Genetics from the University of Alberta in 2012, and also holds an Honours BSc in Biomedical Sciences from the University of Guelph.